Download PDF
Aktuelle Ernährungsmedizin 2002; 27(6): 398-407
DOI: 10.1055/s-2002-35682
Originalarbeit
© Georg Thieme Verlag Stuttgart · New York

Medikamentöse Strategien zur Gewichtszunahme bei kachektischen Patienten

Drug Strategies for Weight Gain in Cachectic PatientsG.  Zürcher1
  • 1Sektion Ernährungsmedizin und Diätetik, Medizinische Universitätsklinik und Poliklinik Freiburg
Manuskript nach einem Vortrag bei der gemeinsamen Jahrestagung von AKE, DGEM und GESKES Nutrition 2002 in Luzern vom 18. - 20.4.2002
Further Information

Publication History

Publication Date:
22 November 2002 (online)

Also available at
    Permissions and Reprints

Zusammenfassung

Zur Behandlung des Anorexie-Kachexie-Syndroms onkologischer Patienten ist auch eine medikamentöse Therapie indiziert. Maßgebend dafür sind der klinische Zustand und die Wünsche des Patienten. Ziel der Therapie sind vorrangig eine Steigerung von Appetit und Nahrungszufuhr, eine Besserung von Wohlbefinden und Lebensqualität, dann erst von Ernährungsstatus und Überleben. Von den „empfohlenen” Medikamenten steigern Prokinetika den Appetit, verbessern Glukokortikoide und Gestagene Appetit und Wohlbefinden und beeinflussen Gestagene den Ernährungszustand positiv. Gestagene (MA) sind auch am besten untersucht. Von den „neuen” Medikamenten wirken Cannabinoide und Thalidomid auf Appetit, Wohlbefinden und Lebensqualität, Melatonin, nichtsteroidale Antiphlogistika und n-3-Fettsäuren zusätzlich auf den Ernährungszustand und das Überleben. Aufgrund fehlender Wirksamkeit und teilweise negativer Effekte nicht empfohlen wird die Anwendung von Cyproheptadin, Hydrazinsulfat und Pentoxifyllin. Anabole androgene Steroide, β2-Adrenozeptoragonisten, Wachstumshormon und IGF-1 sollen aufgrund widersprüchlicher oder bei Tumorpatienten bisher fehlender Untersuchungen nicht außerhalb von Studien eingesetzt werden.

Abstract

Treatment of the anorexia-cachexia-syndrome of tumor patients also involves drug therapy. The clinical condition and the wishes of the patient determine, which drugs should be used. The goals of treatment are primarily to increase appetite and food consumption, to improve the general well-being and quality of life, and then to raise nutritional status and prolong survival. Of the „recommended” drugs prokinetics increase appetite, glucocorticoids and gestagenes increase appetite and well-being, and gestagenes also have a positive impact on nutritional status. Gestagenes (MA) are also the most fully tested of these drugs. Of the „new” drugs, cannabinoids and thalidomide influence appetite, general well-being, and quality of life, melatonin, non-steroidal antiphologistics and n-3-fatty acids in addition have an impact on nutritional status and survival. Not recommended, owing to ineffectiveness and even negative effects, are cyproheptadine, hydrazine sulfate and pentoxifylline. The application of anabolic androgene steroids, β2-adrenoceptor agonists as well as growth hormone or IGF-1 is recommended only in controlled clinical trials based on inconsistent results respectively till now lacking studies with cancer patients.

Schlüsselwörter

Krebs - Anorexie - Kachexie - medikamentöse Therapie

Key words

Cancer - anorexia - cachexia - drug therapy

Literatur

  • 1 Wilmore D W. Catabolic illness.  N Engl J Med. 1991;  325 (10) 695-702
    PubMedSearch in Google Scholar
  • 2 Fearon K CH, Preston T. Body composition in cancer cachexia.  Infusionstherapie. 1990;  17 (Suppl) 63-66
    PubMedSearch in Google Scholar
  • 3 Nitenberg F, Raynard B. Nutritional support of the cancer patient: issues and dilemmas.  Critical Reviews in Oncology/Hematology. 2000;  34 137-168
    CrossrefPubMedSearch in Google Scholar
  • 4 Sharma R, Anker S. First cachaexia symposium, Berlin, Germany 1st - 2nd december, 2000.  European Journal of Heart Failure. 2001;  3 751-754
    CrossrefPubMedSearch in Google Scholar
  • 5 de Wys N, Begg C, Leven P T, Brand P R, Bennett J M, Bertino J R, Cohen M H, Douglass H O, Engstrom P F. et al . Prognostic effect of weight loss prior to chemotherapy in cancer patients.  Am J Med. 1980;  69 491-497
    PubMedSearch in Google Scholar
  • 6 Fearon K CH, Barber M D, Moses A GW. The cancer cachexia syndrom.  Surgical Oncology Clinics of North America. 2001;  10 (1) 109-126
    PubMedSearch in Google Scholar
  • 7 Tisdale M J. Wasting in cancer.  J Nutr. 1999;  129 243S-246S
    PubMedSearch in Google Scholar
  • 8 Tisdale M J. Cancer anorexia and cachexia.  Nutriton. 2001;  17 438-442
    CrossrefPubMedSearch in Google Scholar
  • 9 Argilés J M, Meijsing S H, Palláres-Trujillo J, Guirao X, López-Soriano F J. Cancer cachexia: a therapeutic approach.  Medical Research Reviews. 2001;  21 (1) 83-101
    PubMedSearch in Google Scholar
  • 10 Padilla C V. Psycholocial aspects of nutrition and cancer.  Surg Clin North America. 1986;  66 1121-1135
    PubMedSearch in Google Scholar
  • 11 Ollenschläger G. Ernährungsprobleme des internistischen Tumorpatienten unter besonderer Berücksichtigung der Vitaminversorgung.  Med Klin. 1995;  90 96-102
    PubMedSearch in Google Scholar
  • 12 Ollenschläger G, Bürger B. Die Bedeutung der natürlichen Ernährung für den Tumorpatienten.  Akt Ernähr Med. 1992;  17 278-284
    PubMedSearch in Google Scholar
  • 13 Ovesen L, Hannibal I, Mortensen E L. The interrelationship of weight loss dietary, intake and quality of life in ambulatory patients with cancer of the lung, breast and ovary.  Nutrition and Cancer. 1993;  19 159-167
    PubMedSearch in Google Scholar
  • 14 Keller U. Von der Katabolie zur Anabolie: Stoffwechselmediatoren und Therapieansätze.  Akt Ernähr Med. 2001;  26 148-152
    Thieme ConnectPubMedSearch in Google Scholar
  • 15 Warren S. The immediate causes of death in cancer.  Am J Med Sci. 1932;  184 610-615
    PubMedSearch in Google Scholar
  • 16 Donaldson S S. Nutrition support as an adjunct to radiation therapy.  JPEN. 1984;  8 302-310
    PubMedSearch in Google Scholar
  • 17 Espat N J, Moldawer L L, Copeland E M. Cytokine-mediated alterations in host metabolism prevent nutritional repletion in cachectic cancer patients.  J of surg Oncol. 1995;  58 77-82
    PubMedSearch in Google Scholar
  • 18 Meguid M M, Yang Z J, Gleason J R. The gut-brain brain-gut axis in anorexia: toward an understanding of food intake regulation.  Nutrition. 1996;  12 57-62
    PubMedSearch in Google Scholar
  • 19 Langhans W, Hrupka B. Interleukins and tumor necrosis factor as inhibitors of food intake.  Neuropeptides. 1999;  33 415-424
    CrossrefPubMedSearch in Google Scholar
  • 20 Inui A. Cancer anorexia-cachexiasyndrom: Are neuropeptides the key?.  Cancer Research. 1999;  59 4493-4501
    PubMedSearch in Google Scholar
  • 21 Plata-Salamán C R. Central nervous system mechanisms contributing to the cachexia-anorexia-syndrom.  Nutrition. 2000;  16 1009-1012
    CrossrefPubMedSearch in Google Scholar
  • 22 Meguid M M, Muscaritoli M, Beverly J L, Yang Z J, Cangiano C, Rossi-Fanelli F. The early cancer anorexia paradigm: changes in plasma free tryptophan and feeding indexes.  JPEN. 1992;  16 56 S-59 S
    PubMedSearch in Google Scholar
  • 23 Hasselgren P O, Fischer J E. The ubiquitin-proteasome pathway. Review of a nouvel intracellular mechanism of muscle breakdown during sepsis and other catabolic conditions.  Annals of Surgery. 1997;  225 (3) 307-316
    CrossrefPubMedSearch in Google Scholar
  • 24 Tisdale M J. Protein loss in cancer cachexia.  Science. 2000;  289 2293-2294
    CrossrefPubMedSearch in Google Scholar
  • 25 Laviano A, Renvyle T AD, Yang Z J. From laboratory to bedside: new strategies in the treatment of malnutrition in cancer patients.  Nutrition. 1996;  12 (2) 112-122
    CrossrefPubMedSearch in Google Scholar
  • 26 Ottery F D, Walsh D, Strawford A. Pharmacologic management of anorexia - cachexia.  Seminars in Oncology. 1998;  25 (2, Suppl 6) 35-44
    PubMedSearch in Google Scholar
  • 27 Bruera E. Pharmacological treatment of cachexia: any progress?.  Support Care Cancer. 1998;  6 109-113
    PubMedSearch in Google Scholar
  • 28 Gagnon B, Bruera E. A review of the drug treatment of cachexia associated with cancer.  Drugs. 1998;  55 (5) 675-688
    PubMedSearch in Google Scholar
  • 29 Nelson K A. The cancer anorexia-cachexia-syndrome.  Seminars in Oncology. 2000;  27 (1) 64-68
    PubMedSearch in Google Scholar
  • 30 Davis M P, Dickerson D. Cachexia and anorexia: cancer's covert killer.  Support care cancer. 2000;  8 180-187
    CrossrefPubMedSearch in Google Scholar
  • 31 Shiushanker K, Bennet R, Haynie T. Tumor-associatect gastroparesis: correction with metoclopramide.  Am J Surg. 1983;  145 221-225
    CrossrefPubMedSearch in Google Scholar
  • 32 Bruera E, Mac Eachern T, Spachynski K, Le Gatt D, Mac Donald R N, Barbul N, Harsanyi Z, Darke A. Comparison of the efficacy, safety and pharmakokinetics of controlled release and immediate release metoclopramide for the management of chronic nausea in patients with advanced cancer.  Cancer. 1994;  74 3204-3211
    PubMedSearch in Google Scholar
  • 33 Nelson K A, Walsh T D. The use of metoclopramide in anorexia due to the cancer-associated dyspepsia-syndrome (CADS).  J Palli at care. 1993;  9 14-18
    PubMedSearch in Google Scholar
  • 34 Hardy J. Corticosteroids in palliative care.  Eur J Palliat Care. 1998;  5 46-50
    PubMedSearch in Google Scholar
  • 35 Maltoni M, Nanni O, Scarpi E, Rossi D, Serra P, Amadori D. High-dose progestins for the treatment of cancer anorexia-cachexia syndrome: A systematic review of randomised clinical trials.  Annals of Oncology. 2001;  12 289-300
    CrossrefPubMedSearch in Google Scholar
  • 36 Rowland K M, Loprinzi C HL, Shaw E G, Matzsymink A W, Kuross S A, Jung S H, Kugler J W, Tschetter L K, Gosh C, Schaefer P L, Owen D, Washburn J H, Webb T A, Mailliard J A, Jett J R. Randomized double-blind placebo controlled trial of cisplatin and etoposide plus megestrol acetat/placebo in extensive-stage small all lung cancer: A north central cancer treatment group study.  J of clinical Oncology. 1996;  14 (1) 135-141
    PubMedSearch in Google Scholar
  • 37 Loprinzi C L, Kugler J W, Slowan J A, Mailliard J A, Krook J E, Wilwerdin M B, Rowland K M, Camoriano J K, Novotny P J, Christensen B J. Randomized comparison of megestrol acetat versus dexamethasone versus fluoxmesterone for the treatment of cancer anorexia/cachexia.  J of Clinical Oncology. 1999;  17 (10) 3299-3306
    PubMedSearch in Google Scholar
  • 38 Grotenhermen F, Saller R. Cannabis und Cannabinoide in der Medizin. Glossary.  Forsch Komplementärmed. 1999;  6 (S 3) 44
    PubMedSearch in Google Scholar
  • 39 Gorter R W. Cancer cachexia and cannabinoids.  Forsch.Komplementärmed. 1999;  6 (S 3) 31-22
    PubMedSearch in Google Scholar
  • 40 Pertwell R G. Cannabis and cannabinoids: Pharmacology and rationale for clinical use.  Forsch Komplementärmed. 1999;  6 (S 3) 2-15
    PubMedSearch in Google Scholar
  • 41 Lissoni P, Paolorossi F, Tanani G, Barni S, Ardizzoia A, Brivio F, Zubewicz B, Chatikkine V. Is there a role for melatonin in the treatment of neoplastic cachexia?.  European Journal of cancer. 1996;  32 A 1340-1343
    CrossrefPubMedSearch in Google Scholar
  • 42 Lissoni P, Barni S, Mandalà M, Ardizzoia A, Paolorossi F, Vaghi M, Longarini R, Malugani F, Tancini G. Decreased toxicity and increased efficacy of cancer chemotherapy using the pineal hormone melatonin in metastatic solid tumor patients with poor clinical status.  European Journal of Cancer. 1999;  35 1688-1692
    CrossrefPubMedSearch in Google Scholar
  • 43 Mc Millan D C, Leen E, Smith J, Sturgeon C M, Preston T, Cooke T G, McArdle C S. Effect of extended ibuprofen administration on cortisol, interleukin-6 and the acute-phase protein response in colorectal cancer patients.  Eur J Surg Oncol. 1995;  21 531-534
    CrossrefPubMedSearch in Google Scholar
  • 44 Preston T, Fearon K CH, Mc Millan D C, Winstanley F P, Slater R, Shenkin A, Carter D C. Effect of ibuprofen in the acute-phase response and protein metabolism in patients with cancer and weight loss.  Br J Surg. 1995;  82 229-234
    PubMedSearch in Google Scholar
  • 45 Wigmore S J, Falconer J S, Plester C E, Ross J A, Maingay J P, Carter D C, Fearon K CH. Ibuprofen reduces energy expenditure and acute-phase protein production compared with placebo in pancreatic cancer patients.  British Journal of Cancer. 1995;  72 185-188
    PubMedSearch in Google Scholar
  • 46 Mc Millan D C, O'Gormann P, Fearon K CH, Mc Ardle C S. A pilot study of megestrol acetate and ibuprofen in the treatment of cachexia in gastrointestinal cancer patients.  British Journal of Cancer. 1997;  76 (6) 788-790
    PubMedSearch in Google Scholar
  • 47 Lundholm K, Gelin J, Hyltander A, Lonroth C, Sandstrom R, Svaninger G, Korner U, Gulich M, Karrefors J, Norli B. Antiinflammatory treatment may prolong survival in undernourished patients with metastatic solid tumors.  Cancer Research. 1994;  54 5602-5606
    PubMedSearch in Google Scholar
  • 48 Bruera E, Neumann C M, Pituskin E, Calder K, Ball G, Hanson J. Thalidomide in patients with cachexia due to terminal cancer: reliminary report.  Annals of Oncology. 1999;  10 857-859
    PubMedSearch in Google Scholar
  • 49 Fürst P, Kuhn K S. Fish oil emulsions: what benefits can they bring?.  Clinical Nutriton. 2000;  19 (1) 7-14
    PubMedSearch in Google Scholar
  • 50 Wigmore S J, Fearon K CH, Maingay J P, Ross J A. Down-regulation of the acute-phase response in patients with pancreatic cancer cachexia receiving oral eicosapentaenic acids mediated via suppression of interleukin-6.  Clin Science. 1997;  92 215-221
    PubMedSearch in Google Scholar
  • 51 Wigmor S J, Ross J A, Falconner J S, Plester C E, Tisdale M J, Carter D C, Fearon K CH. The Effect of polyunsaturated fatty acids on the progress of cachexia in patients with pancreatic cancer.  Nutrition. 1996;  12 S27-S30
    PubMedSearch in Google Scholar
  • 52 Tisdale M J. Inhibition of lipolysis and muscle protein degradation by EPA in cancer cachexia.  Nutriton. 1996;  12 S31-S33
    PubMedSearch in Google Scholar
  • 53 Barber M D. Cancer cachexia and its treatment with fish-oil enriched nutritional supplementation.  Nutrition. 2001;  17 751-755
    CrossrefPubMedSearch in Google Scholar
  • 54 Wigmore S J, Barber M D, Ross J A, Tisdale M J, Fearon K CH. Effect of oral eicosapentaenic acid on weight loss in patients with pancreatic cancer.  Nutrition and Cancer. 2000;  36 (2) 177-184
    CrossrefPubMedSearch in Google Scholar
  • 55 Gogos C A, Ginopoulos P, Salsa B, Enterpi A, Nikolas C Z, Fotis K. Dietary omega-3-polyunsaturated fatty acids plus vitamin E restore immundeficiency and prolong survival for severely ill patients with generalized malignancy.  Cancer. 1998;  2 (2) 395-402
    PubMedSearch in Google Scholar
  • 56 Barber M D, Ross J A, Voss A C, Tisdale M J, Fearon K CH. The effect of an oral nutritional supplement enriched with fish oil on weight-loss in patients with pancreatic cancer.  British Journal of Cancer. 1999;  81 (1) 80-86
    PubMedSearch in Google Scholar
  • 57 Barber M D, Ross J A, Preston T, Shenkin A, Fearon K CH. Fish-oil enriched nutritional supplement attenuates progression of the acute phase response in weight-losing patients with advanced pancreatic cancer.  J Nutr. 1999;  129 1120-1125
    PubMedSearch in Google Scholar
  • 58 Barber M D, Mc Millan D C, Preston T, Ross J A, Fearon K CH. The metabolic response to feeding in weight-losing pancreatic cancer patients and its modulation by a fish-oil-enriched nutritional supplement.  Clin Science. 2000;  98 389-399
    PubMedSearch in Google Scholar
  • 59 Federation of the French Cancer Centres (FNCLCC) . Work group. Standards, Options and Recommendations (SOR) for the use of appetit stimulants in oncology.  Bulletin du Cancer. 2000;  87 (4) 315-328
    PubMedSearch in Google Scholar
  • 60 Kardinal C G, Loprinzi C L, Schaid D J, Haas A C, Dose A M, Athmann L H, Mailliard J A, Mc Cormack G W, Gerstner J B, Schray M F. A controlled trial of cyproheptadi-ne in cancer patients with anorexia and/or cachexia.  Cancer. 1990;  65 2657-2662
    CrossrefPubMedSearch in Google Scholar
  • 61 Edelmann M J, Gandara D R, Meyers F J, Ishii R, O'Mahony M, Uhrich M, Lauder J, Houston J, Gietzen D W. Serotonergic blockade in the treatment of the cancer anorexia-cachexia syndrome.  Cancer. 1999;  86 684-688
    CrossrefPubMedSearch in Google Scholar
  • 62 Tayek J A, Heber D, Chlebowski R T. Effect of hydrazine sulphate on whole-body protein breakdown measured by 14C-lysine metabolism in lung cancer patients.  Lancet. 1987;  2 241-244
    PubMedSearch in Google Scholar
  • 63 Chlebowski R T, Bulcavage L, Grosvenor M, Tsunokai R, Block J B, Heber D, Scrooc M, Chlebowski J S, Chi J, Oktay E. Hydrazine Sulfate in cancer patients with weight loss. A placebo-controlled clinical experience.  Cancer. 1987;  59 (3) 406-410
    PubMedSearch in Google Scholar
  • 64 Chlebowski R T, Bulcavage L, Grosvenor M, Oktay E, Block J B, Chlebowski J S, Ali J, Elashoff R. Hydrazine sulfate influence on nutritional status and survival in non-small-cell lung cancer.  J Clin Oncol. 1994;  12 (6) 9-15
    PubMedSearch in Google Scholar
  • 65 Kosty M P, Fleishman S B, Herndon J E, Coughlin K, Kornblith A, Scalzo A B, Morris J C, Mortimer J, Green M R. Cisplatin,vinblastine and hydrazine sulfat in advanced, non-small-cell lung cancer: a randomized, placebo-controlled, double-blind phase III study of the Cancer and Leukemia Group B.  J Clin Oncol. 1994;  12 (6) 1113-1120
    PubMedSearch in Google Scholar
  • 66 Loprinzi C L, Kuross S A, O'Fallon J R, Gesme D, Gerstner J B, Rospond R M, Cobau C D, Goldberg R M. Randomized placebo-controlled evaluation of hydrazine sulfate in patients with advanced colorectal cancer.  J Clin Oncol. 1994;  12 (6) 1121-1125
    PubMedSearch in Google Scholar
  • 67 Loprinzi C L, Goldberg R M, Su J Q, Mailliard J A, Kuross S A, Maksymiuk A W, Kugler J W, Jett J R, Ghosh C, Pfeifle D M. Placebo-controlled trial of hydrazine sulfate in patients with newly diagnosed non-small-cell lung cancer.  J Clin Oncol. 1994;  12 (6) 1126-1129
    PubMedSearch in Google Scholar
  • 68 Dezube B J, Sherman M L, Fridovich-Keil J L, Allen-Ryan J, Pardee A B. Down-regulation of tumor necrosis factor expression by pentoxifylline in cancer patients: a pilot study.  Cancer Immunol Immunother. 1993;  36 (1) 57-60
    PubMedSearch in Google Scholar
  • 69 Lissoni P, Ardizzoia A, Perego M S, Grassi M G, Arosio M, D'Amico P, Cazzaniga M, Crispino S, Tancini G, Barni S. Inhibition of tumor necrosis factor-alpha secretion by pentoxifylline in advanced cancer patients with abnormally high blood levels of tumor necrosis factor-alpha.  J Biol Regul Homeostatic Agents. 1993;  7 73-75
    PubMedSearch in Google Scholar
  • 70 Goldberg R M, Loprinzi C L, Mailliard J A, O'Fallon J R, Krook J E, Ghosh C, Hestorff R O, Chong S F, Reuter N F, Shanahan T G. Pentoxifylline for treatment of cancer anorexia and cachexia? A randomized, double-blind, placebo-controlled trial.  J Clin Oncol. 1995;  13 (11) 2856-2859
    PubMedSearch in Google Scholar
  • 71 Langer C J, Hoffmann J P, Ottery F D. Clinical significance of weight loss in cancer patients:rationale for use of anabolic agents in the treatment of cancer-related cachexia.  Nutrition. 2001;  17 (1 Suppl) 1-20
    CrossrefPubMedSearch in Google Scholar

Dr. G. Zürcher

Sektion Ernährungsmedizin und Diätetik · Universitätsklinik Freiburg · Abt. 1 - Hämatologie, Onkologie

Hartmannstraße 1

79106 Freiburg